Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
19 clinical trials · Sponsor
◉ Watch Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
| Record | Firm | Date |
|---|---|---|
| A Phase 1, Open-Label, 10 Day Safety Study (NCT01623401) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-05-17 |
| A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response (NCT01577459) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-04-23 |
| A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (NCT01519778) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-02-15 |
| A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge (NCT01539473) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-02-01 |
| Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects (NCT01496677) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-01-17 |
| A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects (NCT01461460) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-11-28 |
| A Pharmacokinetics and Safety Study in Subjects With Renal Impairment (NCT01452828) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-10-01 |
| TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (NCT01421511) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-09-15 |
| A PK and Safety Study in Subjects With Hepatic Impairment (NCT01431833) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-08-01 |
| Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg (NCT01271998) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-12-08 |
| Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects (NCT01442831) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-09-09 |
| TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (NCT01170221) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-08-15 |
| Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients (NCT01156077) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-06-02 |
| Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (NCT00983255) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2009-09-01 |
| Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate (NCT00876655) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2009-02-01 |
| Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections (NCT00761215) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2008-09-17 |
| Microdialysis and Pharmacokinetic Study of TR-701 (NCT00666601) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2008-04-04 |
| Food Effects of Single Oral Dose of 600mg TR-701 (NCT00671359) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2008-03-10 |
| Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults (NCT00671814) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2008-01-06 |
Track Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) automatically
Every clearance here is in the API, with alerts when new ones post.